Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

TCGA Identifies Four Stomach Cancer Subtypes

July 24, 2014 10:51 am | News | Comments

Stomach cancers fall into four distinct molecular subtypes researchers with The Cancer Genome Atlas (TCGA) Network have found: a discovery that could change how researchers think about developing treatments for stomach cancer, also called gastric cancers or gastric adenocarcinomas. Read more...

TOPICS:

Developing Multi-Functional Anti-Inflammatory Drugs

July 24, 2014 10:44 am | by Gur Roshwalb, M.D., Chief Executive Officer of Celsus Therapeutics | Articles | Comments

Recent years have witnessed the development of novel, non-steroidal anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs) focusing has been on one of the most sought-after pharmaceutical targets in inflammation research: the secretory phospholipase A2 family. Read more...

TOPICS:

FDA Approves Malignant Hyperthermia Drug

July 23, 2014 2:57 pm | News | Comments

Eagle Pharmaceuticals Inc. announced that the FDA has approved Ryanodex (dantrolene sodium) for injectable suspension indicated for the treatment of malignant hyperthermia, along with the appropriate supportive measures. Read more...      

TOPICS:
Advertisement

Inovio's HPV Immunotherapy Hits Primary Endpoint

July 23, 2014 2:35 pm | News | Comments

Inovio Pharmaceuticals Inc. announced successful results from Phase 2 trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Read more...         

TOPICS:

Oral Cancer Drug May be Potential Alzheimer’s Therapy

July 23, 2014 2:26 pm | News | Comments

Scientists are now reporting new progress on a set of compounds, initially developed for cancer treatment, that shows promise as a potential oral therapy for Alzheimer’s. Read more...                    

TOPICS:

Head of Troubled CDC Anthrax Lab Resigns

July 23, 2014 2:09 pm | News | Comments

The head of the government lab which potentially exposed workers to live anthrax has resigned, an agency spokesman said Wednesday. Michael Farrell was head of the Centers for Disease Control and Prevention lab since 2009. He submitted his resignation Tuesday, the spokesman said. Read more...

TOPICS:

Survey Finds Sharp Increase in Teen HGH Use

July 23, 2014 1:31 pm | by David Crary, AP National Writer | News | Comments

Experimentation with human growth hormones by America's teens more than doubled in the past year, as more young people looked to drugs to boost their athletic performance and improve their looks, according to a new survey. Read more...     

TOPICS:

FDA Approves Gilead's Zydelig for Three Cancers

July 23, 2014 1:13 pm | News | Comments

The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma. Read more...            

TOPICS:
Advertisement

Neurotrophic Keratitis Drug Gets Orphan Drug Designation

July 23, 2014 11:26 am | News | Comments

Dompe, a leader in R&D for new therapeutic solutions for the treatment of rare diseases, announced that rhNGF (Recombinant Human Nerve Growth Factor) has been designated as an orphan drug by the American Food and Drug Administration. Read more...

TOPICS:

Shire to Spend About $225M on Drug Collaboration

July 23, 2014 11:20 am | News | Comments

The drugmaker Shire plans to spend about $225 million in a joint effort with a privately held, U.S. firm to develop a potential treatment for the rare and life-threatening genetic disorder Hunter syndrom, said the British company Wednesday. Read more...

TOPICS:

Genes Play a Role in Radiation Survival

July 23, 2014 11:16 am | News | Comments

A team of researchers from the University of Wisconsin have identified 46 genes in Escherichia coli that are necessary for its survival at exceptionally high levels of radiation. The paper appears ahead of print in the Journal of Bacteriology. Read more...

TOPICS:

Biosceptre Posts Positive Results for Basal Cell Carcinoma Drug

July 23, 2014 11:07 am | News | Comments

Biosceptre, the oncology company developing antibody products that target the nf-P2X7 receptor, announced positive results from its Phase 1 trial to assess the safety and tolerability of BIL-010t, a topically administered, highly purified sheep antibody therapy, to treat Basal Cell Carcinoma. Read more...

TOPICS:

Merck Strengthens Commitment to Chinese Market

July 23, 2014 11:01 am | News | Comments

Merck, a leading company for high-tech products in the pharmaceutical and chemical sectors, reiterated its commitment to investments in the Chinese market, strengthening a major pillar of its emerging markets growth strategy. Read more...   

TOPICS:

Autoimmune Disorders, Cancer Share Apoptosis Inhibitors

July 23, 2014 10:53 am | News | Comments

Autoimmune disorders may share certain pathogenic mechanisms with cancer, according to a new report by George Washington University researcher Linda Kusner, Ph.D., published in PLOS ONE, showing that the very same inhibitors of apoptosis, or cell destruction, in tumors are also expressed in cells that produce autoimmune diseases. Read more...

TOPICS:

Galmed Gets IND Clearance for Fatty Liver Treatment

July 22, 2014 2:47 pm | News | Comments

Galmed Pharmaceuticals Ltd. announced that FDA cleared Galmed's Investigational New Drug application, permitting the company to conduct clinical trials of aramchol in the United States for the treatment of fatty liver disorders. Read more...   

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading